BioCentury
ARTICLE | Politics, Policy & Law

FDA, FTC vow to crack down on advertising and commercial practices that impede biosimilar uptake

February 3, 2020 9:55 PM UTC
Updated on Feb 4, 2020 at 1:38 AM UTC

FDA and FTC Monday said they will crack down on false and misleading advertising that denigrate biosimilars and will act to prevent commercial practices that delay or block biosimilar competition.

FTC said it will “review patent settlement agreements involving biologics, including biosimilars, for antitrust violations,” including pay-for-delay deals that slow or impede the launch of biosimilars. ...